RadNetRDNT
RDNT
About: RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.
Employees: 11,021
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
803% more call options, than puts
Call options by funds: $72.4M | Put options by funds: $8.01M
21% more repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 102
5.98% more ownership
Funds ownership: 86.28% [Q4 2024] → 92.25% (+5.98%) [Q1 2025]
7% less funds holding
Funds holding: 326 [Q4 2024] → 303 (-23) [Q1 2025]
24% less capital invested
Capital invested by funds: $4.46B [Q4 2024] → $3.4B (-$1.06B) [Q1 2025]
29% less first-time investments, than exits
New positions opened: 46 | Existing positions closed: 65
44% less funds holding in top 10
Funds holding in top 10: 9 [Q4 2024] → 5 (-4) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$60
8%
upside
Avg. target
$68
22%
upside
High target
$74
34%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
B. Riley Securities Yuan Zhi | 25%upside $69 | Buy Initiated | 13 Jun 2025 |
Truist Securities David Macdonald | 34%upside $74 | Buy Maintained | 11 Apr 2025 |
Barclays Andrew Mok | 8%upside $60 | Overweight Maintained | 24 Mar 2025 |
Financial journalist opinion
Based on 3 articles about RDNT published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
RadNet Secures $100 Million Incremental Term Loan to Fund Acquisitions and Corporate Initiatives
LOS ANGELES, June 11, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, today announced that it has entered into Incremental Amendment No. 2 (the “Second Amendment”) to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the “Existing Credit Agreement” and, as amended by the Second Amendment, the “Credit Agreement”).
Neutral
GlobeNewsWire
1 week ago
RadNet, Inc. Acquires See-Mode Technologies for Innovation in AI-Powered Ultrasound Diagnostics
LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions through its wholly-owned subsidiary DeepHealth, announced today that it has completed the acquisition of See-Mode Technologies PTE LTD ("See-Mode"), a global innovator in AI for ultrasound imaging. See-Mode's initial applications to detect and characterize thyroid nodules and breast lesions in ultrasound imaging improve diagnostic accuracy and enhance clinical workflows by generating standardized reports.1 These applications and others to be developed in the future using See-Mode's technology and expertise will strengthen DeepHealth's leadership in population health solutions.
Neutral
Business Wire
1 week ago
ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of iCAD, Inc. (NasdaqCM: ICAD) to RadNet, Inc. (NasdaqGM: RDNT). Under the terms of the proposed transaction, shareholders of iCAD will receive 0.0677 shares of RadNet for each share of iCAD that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequat.
Neutral
Seeking Alpha
1 month ago
RadNet, Inc. (RDNT) Q1 2025 Earnings Call Transcript
RadNet, Inc. (NASDAQ:RDNT ) Q1 2025 Earnings Conference Call May 12, 2025 10:30 AM ET Company Participants Mark Stolper - CFO Howard Berger - President and CEO Conference Call Participants Brian Tanquilut - Jefferies Grayson McAlister - Truist Securities Andrew Mok - Barclays Larry Solow - CJS Securities Brandon Carney - B. Riley Operator Good day, and welcome to the RadNet, Inc. First Quarter 2025 Financial Results Conference Call.
Neutral
GlobeNewsWire
1 month ago
RadNet Reports First Quarter Financial Results and Revises Upwards 2025 Financial Guidance Ranges for Revenue and Adjusted EBITDA¹
LOS ANGELES, May 11, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 401 owned and operated outpatient imaging centers, today reported financial results for its first quarter of 2025.
Neutral
GlobeNewsWire
1 month ago
RadNet, Inc. to Present at the Bank of America Securities 2025 Healthcare Conference on May 13th, 2025
LOS ANGELES, May 09, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT ), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the Bank of America Securities 2025 Healthcare Conference in Las Vegas, NV on Tuesday, May 13, 2025 at 5:00 p.m. Pacific Time.
Positive
Seeking Alpha
1 month ago
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
Neutral
GlobeNewsWire
1 month ago
RadNet, Inc. Announces Date of its First Quarter 2025 Financial Results Conference Call
LOS ANGELES, April 24, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its first quarter 2025 financial results on Monday, May 12, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).
Neutral
Business Wire
1 month ago
ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of iCAD, Inc. (NasdaqCM: ICAD) to RadNet, Inc. (NasdaqGM: RDNT). Under the terms of the proposed transaction, shareholders of iCAD will receive 0.0677 shares of RadNet for each share of iCAD that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequat.
Neutral
GlobeNewsWire
2 months ago
RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer
LOS ANGELES and NASHUA, N.H., April 15, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, and iCAD, Inc. (NASDAQ: ICAD) (“iCAD”), a global leader in providing clinically proven AI-powered breast health solutions, announced today that they have entered into a definitive merger agreement under which RadNet will acquire iCAD in an all stock transaction.
Charts implemented using Lightweight Charts™